The U.S. House of Representatives is set to tackle a broad legislative agenda this week, beginning Monday, July 20, with votes postponed until 6:30 p.m. on the first day. The schedule, outlined by Majority Leader Steve Scalise, includes consideration of numerous bills under suspension of the rules, focusing on areas from campaign finance transparency to public health and government efficiency.
Key legislation under suspension includes the Campaign Finance Transparency Act (H.R. 8720), the Destruction of Hazardous Imports Act (H.R. 2715), and the FDA Modernization Act 3.0 (H.R. 2821). Several health-related reauthorization acts are also on the docket, such as the Kay Hagan Tick Act, the Stem Cell Therapeutic and Research Reauthorization Act of 2025, and the School-Based Health Centers Reauthorization Act of 2026. Bills addressing Alzheimer's, traumatic brain injuries, and ALS research are also slated for consideration.
Later in the week, the House will consider significant legislation pursuant to a rule, including the National Defense Authorization Act for Fiscal Year 2027 (H.R. 8800) and a concurrent resolution establishing the congressional budget for fiscal year 2027 through 2036. Other bills include the Main Street Capital Access Act (H.R. 6955), the Stop Insider Trading Act (H.R. 7008), and the Removing Barriers to Work for Disabled Americans Act (H.R. 8884). A Continuing Appropriations Act for 2027 is also expected.
The legislative week will conclude with last votes anticipated no later than 3:00 p.m. on Thursday.